Alector Revenue and Competitors
Estimated Revenue & Valuation
- Alector's estimated annual revenue is currently $197.9M per year.
- Alector received $133.0M in venture funding in July 2018.
- Alector's estimated revenue per employee is $744,135
- Alector's total funding is $194.5M.
- Alector's current valuation is $1.4B. (January 2022)
Employee Data
- Alector has 266 Employees.
- Alector grew their employee count by -11% last year.
Alector's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer | Reveal Email/Phone |
5 | Chief Business Officer | Reveal Email/Phone |
6 | VP, Financial Planning & Portfolio Valuation | Reveal Email/Phone |
7 | SVP, Biometrics | Reveal Email/Phone |
8 | SVP, Head Clinical Development, Neurology | Reveal Email/Phone |
9 | VP, Technical Operations & Supply Chain | Reveal Email/Phone |
10 | VP, Clinical Development Operations | Reveal Email/Phone |
Alector Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 30 | -29% | N/A | N/A |
What Is Alector?
We are ambitious. We are curious. We are pioneers. At Alector we are forging a new path for overcoming the tremendous burden caused by neurodegenerative diseases and cancer. Our approach centers on mining the human genome to identify mutations in immune system genes that increase the risk for these disorders. From there, we are innovating new drugs that counteract the damage these mutations cause. Alector is a privately-owned biotechnology based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.
keywords:Biotechnology,Finance,Healthcare,Pharmaceuticals
$194.5M
Total Funding
266
Number of Employees
$197.9M
Revenue (est)
-11%
Employee Growth %
$1.4B
Valuation
N/A
Accelerator
Alector News
Shares of Alector, Inc. (NASDAQ:ALEC Get Rating) have earned a consensus rating of Buy from the eight brokerages that are presently...
Alector has a novel approach to neurodegenerative diseases. Alector thinks that the immune system gone wrong causes those diseases.
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of...
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29.7M | 266 | 12% | N/A |
#2 | $71.8M | 288 | 6% | $306M |
#3 | $10.1M | 300 | -13% | N/A |
#4 | $69M | 321 | 15% | $743M |
#5 | $195.4M | 348 | -1% | N/A |
Alector Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-11-01 | $Undisclosed | A | Polaris Venture Partners | Article |
| 2015-09-17 | $32.3M | C | Multiple | Article |
| 2016-01-08 | $29.5M | D | Dementia Discovery Fun | Article |
| 2018-07-26 | $133.0M | E | Multiple | Article |